BI 907828 manufacturers
- Brigimadlin
-
- $162.00
-
2026-07-27
- CAS:2095116-40-6
- Purity: 98.17%
- Supply Ability: 10g
|
| | BI 907828 Basic information |
| Product Name: | BI 907828 | | Synonyms: | spiro[3H-indol-3,2'(1'H)-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-7'-carbonsure, 6-chlor-3'-(3-chlor-2-fluorophenyl)-1'-(cyclopropylmethyl)-1,2,3',3'a,10',10'a-hexahydro-6'-methyl-2-oxo-, (3S,3'S,3a'S,10a'S)-;BI 907828;BI-907828 (BRIDIMADLIN);Brigimadlin（BI 907828）;(3S,3'S,3a'S,10a'S)-6-Chloro-3'-(3-chloro-2-fluorophenyl)-1'-(cyclopropylmethyl)-6'-methyl-2-oxo-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazole]-7'-carboxylic acid;Brigimadlin;(2′S,3′S,3′aS,10′aS)-6-Chloro-3′-(3-chloro-2-fluorophenyl)-1′-(cyclopropylmethyl)-1,2,3′,3′a,10′,10′a-hexahydro-6′-methyl-2-oxospiro[3H-indole-3,2′(1′H)-pyrrolo[2′,3′:4,5]pyrrolo[1,2-b]indazole]-7′-carboxylic acid (ACI) | | CAS: | 2095116-40-6 | | MF: | C31H25Cl2FN4O3 | | MW: | 591.46 | | EINECS: | 826-645-5 | | Product Categories: | | | Mol File: | 2095116-40-6.mol |  |
| | BI 907828 Chemical Properties |
| Boiling point | 788.0±60.0 °C(Predicted) | | density | 1.68±0.1 g/cm3(Predicted) | | pka | 3.29±0.40(Predicted) | | form | Solid | | color | White to off-white | | InChIKey | AMTXDBGKYPDTTA-XUOXQPGYNA-N | | SMILES | C(C1CC1)N1[C@@]2([H])CC3=C4C=CC(C(=O)O)=C(C)C4=NN3[C@@]2([H])[C@H](C2C=CC=C(Cl)C=2F)[C@@]21C(NC1=CC(Cl)=CC=C21)=O |&1:5,21,23,32,r| |
| | BI 907828 Usage And Synthesis |
| Description | Brigimadlin is an E3 ubiquitin-protein ligase Mdm2 inhibitor with potential as an antineoplastic agent. | | Uses | Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research[1][2][3][4]. | | in vivo | Brigimadlin (15 and 50 mg/kg, p.o., once a week) inhibits tumor growth and increases median survival in orthotopic xenografts of both a MDM2 amplified (BT48) and a normal CN (BT67), TP53 wild-type BTSC model[3].
Brigimadlin (50 mg/kg, p.o., a single dose) increasees PD biomarkers (CDKN1a and GDF15) in the brain in orthotopic GBM patient-derived BTSC models (BT48 and BT67) in SCID mice, and has low systemic clearance[3].
| | References | [1] Gollner Andreas, et al. Preparation of spiroindolepyrrolidinone derivatives for use as MDM2-p53 inhibitors: World Intellectual Property Organization, WO2017060431. 2017-04-13.
[2] WHO Drug Information-World Health Organization (WHO).
[3] Hao X, et al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol. 2023 May 4;25(5):913-926. DOI:10.1093/neuonc/noac271
[4] Yoo C, et al. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024 Jan 12. DOI:10.2217/fon-2023-0963 |
| | BI 907828 Preparation Products And Raw materials |
|